...
search icon
fold-img

Amicus Therapeutics Inc, Common Stock

FOLD

NMQ

$9.005

-$0.07

(-0.77%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.78B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.78M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.69
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$8.54 L
$12.65 H
$9.005

About Amicus Therapeutics Inc, Common Stock

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameFOLDSectorS&P500
1-Week Return1.18%1.44%0.52%
1-Month Return-2.01%0.4%-5.73%
3-Month Return-8.49%5.95%-4.95%
6-Month Return-19.74%-4.79%-0.96%
1-Year Return-22.97%0.94%8.06%
3-Year Return-6.39%7.73%26.89%
5-Year Return3.51%97.01%154.63%
10-Year Return-21.42%96.83%170.17%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue260.89M305.51M329.23M399.36M528.29M[{"date":"2020-12-31","value":49.38,"profit":true},{"date":"2021-12-31","value":57.83,"profit":true},{"date":"2022-12-31","value":62.32,"profit":true},{"date":"2023-12-31","value":75.59,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue31.04M34.47M38.60M37.33M52.94M[{"date":"2020-12-31","value":58.64,"profit":true},{"date":"2021-12-31","value":65.1,"profit":true},{"date":"2022-12-31","value":72.91,"profit":true},{"date":"2023-12-31","value":70.5,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit229.84M271.05M290.63M362.03M475.35M[{"date":"2020-12-31","value":48.35,"profit":true},{"date":"2021-12-31","value":57.02,"profit":true},{"date":"2022-12-31","value":61.14,"profit":true},{"date":"2023-12-31","value":76.16,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin88.10%88.72%88.28%90.65%89.98%[{"date":"2020-12-31","value":97.18,"profit":true},{"date":"2021-12-31","value":97.87,"profit":true},{"date":"2022-12-31","value":97.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":99.26,"profit":true}]
Operating Expenses473.70M470.97M495.06M427.65M450.48M[{"date":"2020-12-31","value":95.68,"profit":true},{"date":"2021-12-31","value":95.13,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.38,"profit":true},{"date":"2024-12-31","value":90.99,"profit":true}]
Operating Income(243.85M)(199.92M)(204.43M)(73.49M)24.88M[{"date":"2020-12-31","value":-980.28,"profit":false},{"date":"2021-12-31","value":-803.67,"profit":false},{"date":"2022-12-31","value":-821.78,"profit":false},{"date":"2023-12-31","value":-295.44,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(49.60M)(73.60M)(71.71M)(117.64M)(97.82M)[{"date":"2020-12-31","value":-4959900000,"profit":false},{"date":"2021-12-31","value":-7359600000,"profit":false},{"date":"2022-12-31","value":-7170800000,"profit":false},{"date":"2023-12-31","value":-11764500000,"profit":false},{"date":"2024-12-31","value":-9782300000,"profit":false}]
Pre-Tax Income(274.25M)(241.55M)(242.04M)(150.10M)(28.76M)[{"date":"2020-12-31","value":-27425400000,"profit":false},{"date":"2021-12-31","value":-24155400000,"profit":false},{"date":"2022-12-31","value":-24203900000,"profit":false},{"date":"2023-12-31","value":-15010100000,"profit":false},{"date":"2024-12-31","value":-2875600000,"profit":false}]
Income Taxes2.60M8.91M(5.47M)1.48M27.35M[{"date":"2020-12-31","value":9.5,"profit":true},{"date":"2021-12-31","value":32.56,"profit":true},{"date":"2022-12-31","value":-20,"profit":false},{"date":"2023-12-31","value":5.42,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(276.85M)(250.46M)(236.57M)(151.58M)(56.11M)[{"date":"2020-12-31","value":-27685200000,"profit":false},{"date":"2021-12-31","value":-25046000000,"profit":false},{"date":"2022-12-31","value":-23656800000,"profit":false},{"date":"2023-12-31","value":-15158400000,"profit":false},{"date":"2024-12-31","value":-5610600000,"profit":false}]
Income From Continuous Operations(276.85M)(250.46M)(236.57M)(173.61M)(56.11M)[{"date":"2020-12-31","value":-27685200000,"profit":false},{"date":"2021-12-31","value":-25046000000,"profit":false},{"date":"2022-12-31","value":-23656800000,"profit":false},{"date":"2023-12-31","value":-17360600000,"profit":false},{"date":"2024-12-31","value":-5610600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(276.85M)(250.46M)(236.57M)(151.58M)(56.11M)[{"date":"2020-12-31","value":-27685200000,"profit":false},{"date":"2021-12-31","value":-25046000000,"profit":false},{"date":"2022-12-31","value":-23656800000,"profit":false},{"date":"2023-12-31","value":-15158400000,"profit":false},{"date":"2024-12-31","value":-5610600000,"profit":false}]
EPS (Diluted)(1.04)(0.92)(0.82)(0.51)(0.14)[{"date":"2020-12-31","value":-104,"profit":false},{"date":"2021-12-31","value":-92,"profit":false},{"date":"2022-12-31","value":-82,"profit":false},{"date":"2023-12-31","value":-51,"profit":false},{"date":"2024-12-31","value":-14,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

FOLD
Cash Ratio 1.68
Current Ratio 3.39
Quick Ratio 2.60

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

FOLD
ROA (LTM) 2.72%
ROE (LTM) -31.68%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

FOLD
Debt Ratio Lower is generally better. Negative is bad. 0.75
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.25

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

FOLD
Trailing PE NM
Forward PE 500.00
P/S (TTM) 5.28
P/B 14.38
Price/FCF NM
EV/R 5.65
EV/Ebitda 101.52
PEG NM

FAQs

What is Amicus Therapeutics Inc share price today?

Amicus Therapeutics Inc (FOLD) share price today is $9.005

Can Indians buy Amicus Therapeutics Inc shares?

Yes, Indians can buy shares of Amicus Therapeutics Inc (FOLD) on Vested. To buy Amicus Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in FOLD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Amicus Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Amicus Therapeutics Inc (FOLD) via the Vested app. You can start investing in Amicus Therapeutics Inc (FOLD) with a minimum investment of $1.

How to invest in Amicus Therapeutics Inc shares from India?

You can invest in shares of Amicus Therapeutics Inc (FOLD) via Vested in three simple steps:

  • Click on Sign Up or Invest in FOLD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Amicus Therapeutics Inc shares
What is Amicus Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Amicus Therapeutics Inc (FOLD) is $12.65. The 52-week low price of Amicus Therapeutics Inc (FOLD) is $8.54.

What is Amicus Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Amicus Therapeutics Inc (FOLD) is 14.38

What is the Market Cap of Amicus Therapeutics Inc?

The market capitalization of Amicus Therapeutics Inc (FOLD) is $2.78B

What is Amicus Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Amicus Therapeutics Inc is FOLD

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top